Study of Eszopiclone and CPAP Therapy Effects on Sleep Apnea and Brain Function in Adults with Obstructive Sleep Apnea

What this Trial Is About

Researchers are studying adults with obstructive sleep apnea OSA who have an Apnea-Hypopnea Index AHI of 10 or higher per hour of sleep. The study aims to find out if raising the arousal threshold ArTH using eszopiclone affects how well people stick to continuous positive airway pressure CPAP therapy and improve cognitive functions like attention and executive control. The study also explores how baseline arousal threshold levels may relate to CPAP adherence and neurocognitive outcomes. Participants will be randomly assigned to receive either eszopiclone or a placebo on the night of a split-night polysomnography test, which monitors sleep with and without CPAP therapy. After this laboratory night, they will continue to take eszopiclone or placebo along with CPAP therapy over three months. The eszopiclone dose is 3 mg for those under 65 years and 2 mg for those 65 and older. The study uses a quadruple masking design to compare the effects. During the study, participants will have daily CPAP adherence tracked for three months and undergo several cognitive tests including the Flanker Inhibitory Control test at baseline and monthly intervals. Researchers will also measure cardiovascular function, sleep quality, hypoxia levels, and biomarkers related to neuronal damage and stress at various times. Safety and tolerance to treatment will be monitored, with assessments continuing through the study duration of up to three months.

Continuous Positive Airway Pressure, Arousability and Links to Mechanisms in Obstructive Sleep Apnea